View More Recent Stories
-
BTIG Reiterates Buy Rating on Evolent Health (EVH)
-
RBC Capital Reiterates Outperform Rating on Evolent Health (EVH), discusses M&A chatter
-
Evolent Health (EVH) October 27.50 and 32.50 calls active after Reuters says in sale talks
-
Evolent Health (EVH) In Sale Talks After Inbound Interest - Reuters
-
Truist Securities Upgrades Evolent Health (EVH) to Buy
-
Evolent Health (EVH) Tops Q2 EPS by 5c; offers guidance
-
RBC Capital Reiterates Outperform Rating on Evolent Health (EVH)
-
TD Cowen Reiterates Buy Rating on Evolent Health (EVH)
-
RBC Capital Reiterates Outperform Rating on Evolent Health (EVH)
-
These stocks are BTIG's Top Picks for 2024

